tradingkey.logo
搜索

Grifols SA

GRFS
添加自选
7.370USD
+0.150+2.08%
收盘 06/25, 16:00美东报价延迟15分钟
1.90B总市值
9.50市盈率 TTM

Grifols SA

7.370
+0.150+2.08%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.08%

5天

-0.41%

1月

-7.64%

6月

-18.38%

今年开始到现在

-21.18%

1年

-13.40%

关键数据
7.300今开
7.370最高
546.69K成交量
9.50市盈率 TTM
2.09市盈率动
0.137股息TTM
0.21%换手率
7.220昨收
7.275最低
2.51M成交额
11.21市盈率静
0.30市净率
1.86%股息率 TTM
2.48%ROA
11.14052周最高
0.70量比
169.72M净利润
258.22M总股本
0.7760每股收益TTM
0.66Beta
7.67%ROE
7.39052周最低
1.32%振幅
36.47%毛利率
1.90B总市值
-6.64回报/风险
1.55%风险率

TradingKey Grifols SA股票评分

单位: USD 更新时间: 2026-06-24

操作建议

Grifols SA当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名66/157位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价11.73。中期看,股价处于平稳状态。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Grifols SA评分

相关信息

行业排名
66 / 157
全市场排名
168 / 4571
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Grifols SA亮点

亮点风险
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
业绩高增长
公司营业收入稳步增长,连续3年增长19.05%
利润高增长
公司净利润处于行业前列,最新年度总收入8.48B美元
估值低估
公司最新PE估值9.30,处于3年历史低位
机构减仓
最新机构持股148.94M股,环比减少5.51%
布兰德斯投资公司持仓
明星投资者布兰德斯投资公司持仓,最新持仓市值63.32M

分析师目标

根据 8 位分析师
买入
评级
11.730
目标均价
+63.37%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Grifols SA新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Grifols SA简介

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
公司代码GRFS
公司Grifols SA
CEOAbia (Jose Ignacio)
网址https://www.grifols.com/

常见问题

Grifols SA(GRFS)的当前股价是多少?

Grifols SA(GRFS)的当前股价是 7.37。

Grifols SA的股票代码是什么?

Grifols SA的股票代码是GRFS。

Grifols SA股票的52周最高点是多少?

Grifols SA股票的52周最高点是11.14。

Grifols SA股票的52周最低点是多少?

Grifols SA股票的52周最低点是7.39。

Grifols SA的市值是多少?

Grifols SA的市值是1.90B。

现在Grifols SA(GRFS)的股票是买入、持有还是卖出?

根据分析师评级,Grifols SA(GRFS)的总体评级为买入,目标价格为11.73。

Grifols SA(GRFS)股票的每股收益(EPS TTM)是多少

Grifols SA(GRFS)股票的每股收益(EPS TTM)是0.67。
KeyAI